{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:55:28Z","timestamp":1787756128683,"version":"build-2784847793"},"reference-count":267,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.prp.2022.153956","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T11:47:39Z","timestamp":1653652059000},"page":"153956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential"],"prefix":"10.1016","volume":"236","author":[{"given":"Liwei","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s42979-021-00898-w","article-title":"Study on different approaches for breast cancer detection: a review","volume":"3","author":"Ravikumar","year":"2022","journal-title":"SN Comput. Sci."},{"key":"10.1016\/j.prp.2022.153956_bib2","unstructured":"Breast cancer: prevention and control. 2021 4\/7\/2021]; Available from: \u3008https:\/\/www.who.int\/cancer\/detection\/breastcancer\/en\/\u3009."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib3","first-page":"311","article-title":"Breast cancer metastasis","volume":"9","author":"Scully","year":"2012","journal-title":"Cancer Genom. Proteom."},{"issue":"15","key":"10.1016\/j.prp.2022.153956_bib4","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.7150\/jca.44313","article-title":"Angiogenesis in breast cancer progression, diagnosis, and treatment","volume":"11","author":"Madu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.prp.2022.153956_bib5","first-page":"15","article-title":"Antiangiogenic mechanisms and factors in breast cancer treatment","author":"Casta\u00f1eda-Gill","year":"2016","journal-title":"J. Carcinog."},{"issue":"24","key":"10.1016\/j.prp.2022.153956_bib6","doi-asserted-by":"crossref","first-page":"39795","DOI":"10.18632\/oncotarget.7794","article-title":"Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?","volume":"8","author":"Coelho","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7326\/0003-4819-136-1-200201010-00011","article-title":"Therapeutic angiogenesis for coronary artery disease","volume":"136","author":"Freedman","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.prp.2022.153956_bib8","series-title":"Seminars in Cancer Biology","article-title":"Epidemiology of breast cancer, a paradigm of the\u201c common soil\u201d hypothesis","author":"Iacoviello","year":"2020"},{"key":"10.1016\/j.prp.2022.153956_bib9","unstructured":"Breast cancer. 2020 10.16.2020]; Available from: \u3008https:\/\/www.who.int\/cancer\/prevention\/diagnosis-screening\/breast-cancer\/en\/\u3009."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10555-010-9247-y","article-title":"Regulatory T cells and breast cancer: implications for immunopathogenesis","volume":"29","author":"Watanabe","year":"2010","journal-title":"Cancer Metastas. Rev."},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib11","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1172\/JCI90499","article-title":"Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer","volume":"127","author":"Taylor","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3889\/oamjms.2018.231","article-title":"Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients","volume":"6","author":"Kondov","year":"2018","journal-title":"Open Access Maced. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-016-3775-2","article-title":"Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes","volume":"157","author":"Purrington","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17249-7","article-title":"Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution","volume":"11","author":"Pommier","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2022.153956_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jnci\/djw144","article-title":"Genomic analysis of immune cell infiltrates across 11 tumor types","volume":"108","author":"Iglesia","year":"2016","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"14","key":"10.1016\/j.prp.2022.153956_bib16","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-13-3368","article-title":"Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer","volume":"20","author":"Iglesia","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s001090050128","article-title":"Multistep carcinogenesis of breast cancer and tumour heterogeneity","volume":"75","author":"Beckmann","year":"1997","journal-title":"J. Mol. Med."},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib18","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.prp.2022.153956_bib21","series-title":"Angiogenesis in Health Disease and Malignancy","first-page":"1","article-title":"Introduction to angiogenesis in normal physiology, disease and malignancy","author":"Salajegheh","year":"2016"},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.bjc.6690755","article-title":"Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?","volume":"81","author":"Linderholm","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.neo.7900186","article-title":"Vegf-a, vegf-c, and vegf-d in colorectal cancer progression","volume":"3","author":"George","year":"2001","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199101033240101","article-title":"Tumor angiogenesis and metastasis\u2014correlation in invasive breast carcinoma","volume":"324","author":"Weidner","year":"1991","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cance","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib27","doi-asserted-by":"crossref","first-page":"C1367","DOI":"10.1152\/ajpcell.2001.280.6.C1367","article-title":"Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis","volume":"280","author":"Dor","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.prp.2022.153956_bib28","series-title":"Cell Polarity 1","first-page":"205","article-title":"Endothelial cell polarization during lumen formation, tubulogenesis, and vessel maturation in 3D extracellular matrices","author":"Davis","year":"2015"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02373-8","article-title":"Polarized actin and VE-cadherin dynamics regulate junctional remodelling and cell migration during sprouting angiogenesis","volume":"8","author":"Cao","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10555-007-9094-7","article-title":"Tumour vascularization: sprouting angiogenesis and beyond","volume":"26","author":"Hillen","year":"2007","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.prp.2022.153956_bib31","first-page":"11","article-title":"Novel pathways for targeting tumor angiogenesis in metastatic breast cancer","author":"Harry","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2020","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1083\/jcb.200408130","article-title":"Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis","volume":"167","author":"Weis","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.prp.2022.153956_bib34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fonc.2013.00211","article-title":"Vascular permeability and drug delivery in cancers","volume":"3","author":"Azzi","year":"2013","journal-title":"Front. Oncol."},{"issue":"33","key":"10.1016\/j.prp.2022.153956_bib35","doi-asserted-by":"crossref","first-page":"25130","DOI":"10.1074\/jbc.M001914200","article-title":"Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1\u03b1 during hypoxia: a mechanism of O2 sensing","volume":"275","author":"Chandel","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.prp.2022.153956_bib36","doi-asserted-by":"crossref","first-page":"11715","DOI":"10.1073\/pnas.95.20.11715","article-title":"Mitochondrial reactive oxygen species trigger hypoxia-induced transcription","volume":"95","author":"Chandel","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2022.153956_bib37","series-title":"Seminars in Cancer Biology","article-title":"The role of reactive oxygen species and metabolism on cancer cells and their microenvironment","author":"Costa","year":"2014"},{"issue":"19","key":"10.1016\/j.prp.2022.153956_bib38","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1073\/pnas.1003428107","article-title":"Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity","volume":"107","author":"Weinberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib39","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.cdd.4402307","article-title":"Mitochondrial complex III regulates hypoxic activation of HIF","volume":"15","author":"Klimova","year":"2008","journal-title":"Cell Death Differ."},{"issue":"23","key":"10.1016\/j.prp.2022.153956_bib40","doi-asserted-by":"crossref","first-page":"11238","DOI":"10.1158\/0008-5472.CAN-06-1278","article-title":"Macrophages regulate the angiogenic switch in a mouse model of breast cancer","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2022.153956_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.3989","article-title":"Vascular endothelial growth factor\u2010induced skin carcinogenesis depends on recruitment and alternative activation of macrophages","volume":"227","author":"Linde","year":"2012","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib43","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1172\/JCI84427","article-title":"The impact of hypoxia on tumor-associated macrophages","volume":"126","author":"Henze","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"7355","key":"10.1016\/j.prp.2022.153956_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"issue":"4s","key":"10.1016\/j.prp.2022.153956_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/imt.11.30","article-title":"IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-\u03b3","volume":"3","author":"Jeannin","year":"2011","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: from basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib47","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1158\/0008-5472.CAN-05-4463","article-title":"Tumor cell\u2013derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer","volume":"66","author":"Vasiljeva","year":"2006","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib48","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00018-008-7462-2","article-title":"Substrate specificity of \u03b3-secretase and other intramembrane proteases","volume":"65","author":"Beel","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/0008-5472.CAN-10-2602","article-title":"Glioblastoma recurrence after cediranib therapy in patients: lack of \u201crebound\u201d revascularization as mode of escape","volume":"71","author":"di Tomaso","year":"2011","journal-title":"Cancer Res."},{"issue":"6382","key":"10.1016\/j.prp.2022.153956_bib50","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1126\/science.aal3622","article-title":"Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice","volume":"359","author":"Pereira","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.prp.2022.153956_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/jnci\/djw030","article-title":"Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma","volume":"108","author":"Kuczynski","year":"2016","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nm.2072","article-title":"Real-time imaging reveals the single steps of brain metastasis formation","volume":"16","author":"Kienast","year":"2010","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.prp.2022.153956_bib53","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/nm.4197","article-title":"Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases","volume":"22","author":"Frentzas","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2022.153956_bib54","series-title":"Seminars in Cancer Biology","article-title":"Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: a theoretical model","author":"Rada","year":"2021"},{"key":"10.1016\/j.prp.2022.153956_bib55","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2147\/CMAR.S164675","article-title":"Overview of advances in vasculogenic mimicry\u2013a potential target for tumor therapy","volume":"10","author":"Ge","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.canlet.2006.08.016","article-title":"Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma","volume":"249","author":"Sun","year":"2007","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib58","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4161\/cbt.19602","article-title":"Vasculogenic mimicry is a marker of poor prognosis in prostate cancer","volume":"13","author":"Liu","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.prp.2022.153956_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/bs.acr.2020.06.001","article-title":"Vascular mimicry: Triggers, molecular interactions and in vivo models","volume":"148","author":"Wechman","year":"2020","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib60","first-page":"15","article-title":"Microcirculation patterns in different stages of melanoma growth","volume":"15","author":"Zhang","year":"2006","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib61","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1097\/00003246-200205001-00013","article-title":"Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension","volume":"30","author":"Voelkel","year":"2002","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib62","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nm846","article-title":"A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2","volume":"9","author":"Qi","year":"2003","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/emboj\/18.2.363","article-title":"A novel vascular endothelial growth factor encoded by Orf virus, VEGF\u2010E, mediates angiogenesis via signalling through VEGFR\u20102 (KDR) but not VEGFR\u20101 (Flt\u20101) receptor tyrosine kinases","volume":"18","author":"Meyer","year":"1999","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib64","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.4049\/jimmunol.1002802","article-title":"Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion","volume":"186","author":"Coffelt","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.prp.2022.153956_bib65","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.prp.2022.153956_bib67","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/cells8121647","article-title":"Myeloid-derived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer","volume":"8","author":"Vetsika","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00312-w","article-title":"Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment","volume":"9","author":"Chen","year":"2021","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib70","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib71","first-page":"963","volume":"57","author":"Relf","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2022.153956_bib72","series-title":"VEGF Isoforms","author":"Perrot-Applanat","year":"2012"},{"issue":"7764","key":"10.1016\/j.prp.2022.153956_bib73","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.prp.2022.153956_bib74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1126\/sciimmunol.aay0555","article-title":"VEGF-A drives TOX-dependent T cell exhaustion in anti\u2013PD-1\u2013resistant microsatellite stable colorectal cancers","volume":"4","author":"Kim","year":"2019","journal-title":"Sci. Immunol."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib75","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccell.2017.10.003","article-title":"An HIF-1\u03b1\/VEGF-A axis in cytotoxic T cells regulates tumor progression","volume":"32","author":"Palazon","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib76","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ijc.11724","article-title":"Identification of interleukin\u20108 as estrogen receptor\u2010regulated factor involved in breast cancer invasion and angiogenesis by protein arrays","volume":"109","author":"Lin","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-3-4","article-title":"Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8\/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress","volume":"3","author":"Marjon","year":"2004","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib78","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cellimm.2010.07.006","article-title":"Expression profile of IL-8 and growth factors in breast cancer cells and adipose-derived stem cells (ASCs) isolated from breast carcinoma","volume":"265","author":"Razmkhah","year":"2010","journal-title":"Cell. Immunol."},{"issue":"16","key":"10.1016\/j.prp.2022.153956_bib79","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.ejca.2004.05.024","article-title":"Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy","volume":"40","author":"Chelouche-Lev","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib80","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1074\/jbc.C800207200","article-title":"CXCL8\/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NF\u03baB through the CBM (Carma3\/Bcl10\/Malt1) complex","volume":"284","author":"Martin","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib81","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.4049\/jimmunol.170.6.3369","article-title":"IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis","volume":"170","author":"Li","year":"2003","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-7682-3-11","article-title":"Interleukin 8 (IL-8)-a universal biomarker?","volume":"3","author":"Shahzad","year":"2010","journal-title":"Int. Arch. Med."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib83","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0006-2952(00)00529-3","article-title":"Angiogenesis: regulators and clinical applications","volume":"61","author":"Liekens","year":"2001","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3354","volume":"14","author":"Linardou","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.prp.2022.153956_bib85","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/746749","article-title":"Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a","author":"Srabovic","year":"2013","journal-title":"Int. J. Breast Cancer"},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib86","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0002-9440(10)65392-8","article-title":"VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer","volume":"154","author":"Valtola","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib87","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/bies.20405","article-title":"Functional diversity of FGF\u20102 isoforms by intracellular sorting","volume":"28","author":"S\u00f8rensen","year":"2006","journal-title":"Bioessays"},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib88","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/17446651.2013.811910","article-title":"The FGF\/FGF receptor axis as a therapeutic target in breast cancer","volume":"8","author":"Brady","year":"2013","journal-title":"Expert Rev. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib89","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.1997.5","article-title":"Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance","volume":"75","author":"Yiangou","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2022.153956_bib90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1749-6632.1994.tb24720.x","article-title":"The family of matrix metalloproteinases","volume":"732","author":"Woessner","year":"1994","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib91","first-page":"273","article-title":"Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response","volume":"149","author":"Heppner","year":"1996","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib92","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-4804(03)00007-6","article-title":"Matrix metalloproteinase expression in breast cancer","volume":"110","author":"Bartsch","year":"2003","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib93","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev.me.41.020190.000505","article-title":"Physiology of thrombospondin","volume":"41","author":"Mosher","year":"1990","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1582-4934.2002.tb00307.x","article-title":"Thrombospondin\u20101 as an endogenous inhibitor of angiogenesis and tumor growth","volume":"6","author":"Lawler","year":"2002","journal-title":"J. Cell. Mol. Med."},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib95","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/jcp.55.8.569","article-title":"Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast","volume":"55","author":"Rice","year":"2002","journal-title":"J. Clin. Pathol."},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib96","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0945-053X(00)00107-4","article-title":"The cell biology of thrombospondin-1","volume":"19","author":"Chen","year":"2000","journal-title":"Matrix Biol."},{"key":"10.1016\/j.prp.2022.153956_bib97","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-3-0348-9006-9_12","article-title":"Thrombospondin as a regulator of angiogenesis","author":"DiPietro","year":"1997","journal-title":"Regul. Angiogenesis"},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib98","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1471-4914(01)02102-5","article-title":"Thrombospondins and tumor angiogenesis","volume":"7","author":"de Fraipont","year":"2001","journal-title":"Trends Mol. Med."},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib99","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0945-053X(00)00104-9","article-title":"Thrombospondin 2, a matricellular protein with diverse functions","volume":"19","author":"Bornstein","year":"2000","journal-title":"Matrix Biol."},{"issue":"5178","key":"10.1016\/j.prp.2022.153956_bib100","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.7521539","article-title":"Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1","volume":"265","author":"Dameron","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.prp.2022.153956_bib101","series-title":"Cold Spring Harbor symposia on quantitative biology","article-title":"The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin","author":"Dameron","year":"1994"},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib102","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0022-2143(98)90131-7","article-title":"Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells","volume":"132","author":"Phelan","year":"1998","journal-title":"J. Lab. Clin. Med."},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib103","first-page":"2941","article-title":"Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor","volume":"6","author":"Laderoute","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.prp.2022.153956_bib104","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1002\/j.1460-2075.1994.tb06905.x","article-title":"SPARC and thrombospondin genes are repressed by the c\u2010jun oncogene in rat embryo fibroblasts","volume":"13","author":"Mettouchi","year":"1994","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib105","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00109-011-0759-x","article-title":"Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development","volume":"89","author":"Cork","year":"2011","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2148-5-11","article-title":"Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization","volume":"5","author":"Nicholson","year":"2005","journal-title":"BMC Evolut. Biol."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib107","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3748\/wjg.v9.i2.262","article-title":"Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome-endostatin complex","volume":"9","author":"Li","year":"2003","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.prp.2022.153956_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110552","article-title":"Encapsulation of an endostatin peptide in liposomes: Stability, release, and cytotoxicity study","volume":"185","author":"Rezaei","year":"2020","journal-title":"Coll. Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib109","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O\u2019Reilly","year":"1997","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1006\/mthe.2000.0243","article-title":"Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice","volume":"3","author":"Scappaticci","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2022.153956_bib111","doi-asserted-by":"crossref","unstructured":"Rehn, M., et al., Interaction of endostatin with integrins implicated in angiogenesis. Proceedings of the National Academy of Sciences, 2001. 98(3): p. 1024\u20131029.","DOI":"10.1073\/pnas.031564998"},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib112","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1006\/mthe.2002.0590","article-title":"Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis","volume":"5","author":"Yin","year":"2002","journal-title":"Mol. Ther."},{"issue":"19","key":"10.1016\/j.prp.2022.153956_bib113","doi-asserted-by":"crossref","first-page":"16464","DOI":"10.1074\/jbc.M112274200","article-title":"Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1","volume":"277","author":"Hanai","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.prp.2022.153956_bib114","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301703","article-title":"Differential effects of angiostatin, endostatin and interferon-\u03b1 1 gene transfer on in vivo growth of human breast cancer cells","volume":"9","author":"Indraccolo","year":"2002","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6467-6","article-title":"Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study","volume":"20","author":"Ge","year":"2020","journal-title":"BMC Cancer"},{"issue":"1\u20132","key":"10.1016\/j.prp.2022.153956_bib116","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.drup.2005.03.001","article-title":"Endostatin: the logic of antiangiogenic therapy","volume":"8","author":"Abdollahi","year":"2005","journal-title":"Drug Resist. Updates"},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib117","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1083\/jcb.200203064","article-title":"Endostatin is a potential inhibitor of Wnt signaling","volume":"158","author":"Hanai","year":"2002","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib118","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2007.06.155","article-title":"Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR\/Flk-1 of endothelial cells","volume":"361","author":"Ling","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib119","first-page":"643","article-title":"Therapeutic potentials of angiostatin in the treatment of cancer","volume":"84","author":"Cao","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2022.153956_bib120","series-title":"Breast Cancer Management and Molecular Medicine","author":"Piccart","year":"2007"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib121","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/rp.59.1.73","article-title":"Angiostatin and anti-angiogenic therapy in human disease","volume":"59","author":"Wahl","year":"2004","journal-title":"Recent Prog. Horm. Res."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib122","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1073\/pnas.96.6.2811","article-title":"Angiostatin binds ATP synthase on the surface of human endothelial cells","volume":"96","author":"Moser","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2022.153956_bib123","doi-asserted-by":"crossref","unstructured":"Wajih, N. and D.C. Sane, Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood, The Journal of the American Society of Hematology, 2003. 101(5): p. 1857\u20131863.","DOI":"10.1182\/blood-2002-02-0582"},{"issue":"1\u20132","key":"10.1016\/j.prp.2022.153956_bib124","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2004.11.063","article-title":"Interferon-mediated anti-angiogenic therapy for neuroblastoma","volume":"228","author":"Streck","year":"2005","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib125","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0002-9440(10)65007-9","article-title":"Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach","volume":"156","author":"Albini","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-12414-3","article-title":"The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis","volume":"7","author":"Enomoto","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib127","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/156652411794859241","article-title":"Decorin biology, expression, function and therapy in the cornea","volume":"11","author":"Mohan, R","year":"2011","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.prp.2022.153956_bib128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.matbio.2015.01.023","article-title":"Pivotal role for decorin in angiogenesis","volume":"43","author":"J\u00e4rvel\u00e4inen","year":"2015","journal-title":"Matrix Biol."},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib129","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1074\/jbc.274.8.4489","article-title":"Decorin is a biological ligand for the epidermal growth factor receptor","volume":"274","author":"Iozzo","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.prp.2022.153956_bib130","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-1190-03","article-title":"Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action","volume":"10","author":"K\u00f6ninger","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib131","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI117806","article-title":"Posttranscriptional stabilization underlies p53-independent induction of p21WAF1\/CIP1\/SDI1 in differentiating human leukemic cells","volume":"95","author":"Schwaller","year":"1995","journal-title":"J. Clin. Investig."},{"issue":"37","key":"10.1016\/j.prp.2022.153956_bib132","doi-asserted-by":"crossref","first-page":"32468","DOI":"10.1074\/jbc.M503833200","article-title":"Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis","volume":"280","author":"Zhu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2022.153956_bib133","series-title":"Tumor Microenvironment","first-page":"17","article-title":"Decorin in the tumor microenvironment","author":"Baghy","year":"2020"},{"key":"10.1016\/j.prp.2022.153956_bib134","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/317068","article-title":"TGF-\u03b2 superfamily receptors\u2014targets for antiangiogenic therapy?","author":"Otten","year":"2010","journal-title":"J. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib135","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1523-1755.2004.00780.x","article-title":"TGF-\u03b2 induces proangiogenic and antiangiogenic factorsvia parallel but distinct Smad pathways","volume":"66","author":"Nakagawa","year":"2004","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib136","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1242\/jcs.002949","article-title":"BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis","volume":"120","author":"Scharpfenecker","year":"2007","journal-title":"J. Cell Sci."},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib137","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib138","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1161\/CIRCRESAHA.107.165530","article-title":"Bone morphogenetic protein-9 is a circulating vascular quiescence factor","volume":"102","author":"David","year":"2008","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib139","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.devcel.2012.02.005","article-title":"ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway","volume":"22","author":"Larriv\u00e9e","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.prp.2022.153956_bib140","doi-asserted-by":"crossref","unstructured":"Lamouille, S., et al., Activin receptor\u2013like kinase 1 is implicated in the maturation phase of angiogenesis. Blood, The Journal of the American Society of Hematology, 2002. 100(13): p. 4495\u20134501.","DOI":"10.1182\/blood.V100.13.4495"},{"issue":"35","key":"10.1016\/j.prp.2022.153956_bib141","doi-asserted-by":"crossref","first-page":"55957","DOI":"10.18632\/oncotarget.11182","article-title":"BMP9\/ALK1 inhibits neovascularization in mouse models of age-related macular degeneration","volume":"7","author":"Ntumba","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2022.153956_bib142","unstructured":"Zhaohua, G., et al., Expression of bone morphogenetic protein 9 and insulin-like growth factor-1 in different molecular subtypes of breast cancer and their correlations with clinical features. \u5b9e\u7528\u4e34\u5e8a\u533b\u836f\u6742\u5fd7, 2021. 25(8): p. 1\u20135, 10."},{"issue":"Suppl 1","key":"10.1016\/j.prp.2022.153956_bib143","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1136\/bjophthalmol-2014-305302","article-title":"Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture","volume":"98","author":"Malik","year":"2014","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib144","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-200868040-00009","article-title":"Bevacizumab","volume":"68","author":"McCormack","year":"2008","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib145","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/fon.10.75","article-title":"Ramucirumab (IMC-1121B): a novel attack on angiogenesis","volume":"6","author":"Spratlin","year":"2010","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib146","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","article-title":"Clinical pharmacology of axitinib","volume":"52","author":"Chen","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib147","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","article-title":"Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene","volume":"3","author":"Pennacchietti","year":"2003","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.prp.2022.153956_bib148","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cancers8110103","article-title":"The receptor tyrosine kinase AXL in cancer progression","volume":"8","author":"Rankin","year":"2016","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib149","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2022.153956_bib150","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"24","key":"10.1016\/j.prp.2022.153956_bib151","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1158\/0008-5472.CAN-10-0489","article-title":"HGF\/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors","volume":"70","author":"Shojaei","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2022.153956_bib152","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.prp.2022.153956_bib153","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.prp.2022.153956_bib154","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.prp.2022.153956_bib155","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1078-0432.CCR-13-2620","article-title":"Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET","volume":"20","author":"Xiang","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib156","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib157","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40265-015-0383-0","article-title":"Lenvatinib: first global approval","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib158","first-page":"443","article-title":"Pazopanib","volume":"71","author":"Keisner","year":"2011","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.prp.2022.153956_bib159","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/bjc.2012.153","article-title":"Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study","volume":"106","author":"Strumberg","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2022.153956_bib160","series-title":"Sorafenib, in profiles of drug substances, excipients and related methodology","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/bs.podrm.2018.11.003","author":"Abdelgalil","year":"2019"},{"key":"10.1016\/j.prp.2022.153956_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.105926","article-title":"Analysis of Sunitinib Malate, a multi-targeted tyrosine kinase inhibitor: a critical review","author":"AboulMagd","year":"2021","journal-title":"Microchem. J."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib162","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","article-title":"Sorafenib","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib163","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib164","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","article-title":"Sunitinib","volume":"23","author":"Papaetis","year":"2009","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib165","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2165\/11595310-000000000-00000","article-title":"Vandetanib","volume":"71","author":"Commander","year":"2011","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib166","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"New Engl. J. Med."},{"issue":"16","key":"10.1016\/j.prp.2022.153956_bib167","first-page":"4573","article-title":"Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells","volume":"60","author":"von Wichert","year":"2000","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib168","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O\u2019Donnell","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib169","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","article-title":"Everolimus","volume":"16","author":"Houghton","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib170","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/0008-5472.CAN-06-2701","article-title":"Hypoxia-inducible factor-1\u03b1 is a key regulator of metastasis in a transgenic model of cancer initiation and progression","volume":"67","author":"Liao","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib171","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","article-title":"The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions","volume":"77","author":"Lu","year":"2009","journal-title":"Microvasc. Res."},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib172","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(94)90007-8","article-title":"Integrin \u03b1v\u03b23 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels","volume":"79","author":"Brooks","year":"1994","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib173","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/ijc.25563","article-title":"Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE\u2010MRI in a longitudinal in vivo study","volume":"128","author":"B\u00e4uerle","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib174","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10637-012-9842-6","article-title":"Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer","volume":"31","author":"Manegold","year":"2013","journal-title":"Investig. New Drugs"},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib176","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s10637-010-9420-8","article-title":"Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium","volume":"29","author":"Bradley","year":"2011","journal-title":"Investig. New Drugs"},{"issue":"7","key":"10.1016\/j.prp.2022.153956_bib177","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0959-8049(03)00057-1","article-title":"Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins \u03b1v\u03b23 and \u03b1v\u03b25 in patients with advanced solid tumours","volume":"39","author":"Eskens","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib178","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/15419069509081020","article-title":"The integrin \u03b1v\u03b23: angiogenesis and apoptosis","volume":"3","author":"Varner","year":"1995","journal-title":"Cell Adhes. Commun."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib179","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11307-010-0302-4","article-title":"Specific targeting of human integrin \u03b1 v \u03b2 3 with 111 In-labeled AbegrinTM in nude mouse models","volume":"13","author":"Liu","year":"2011","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.prp.2022.153956_bib180","article-title":"Integrins as attractive targets for cancer therapeutics","author":"Li","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib181","first-page":"3056","article-title":"Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin \u03b1\u03bd\u03b23","volume":"6","author":"Gutheil","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib182","first-page":"1526","article-title":"A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin \u03b1v\u03b23,\u00b1dacarbazine in patients with stage IV metastatic melanoma","volume":"116","author":"Hersey","year":"2010","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"10.1016\/j.prp.2022.153956_bib183","article-title":"Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance","author":"Liu","year":"2020","journal-title":"Genes Dis."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib184","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF01937766","article-title":"Antitumor activity of the Isodon diterpenoids: structural requirements for the activity","volume":"32","author":"Fujita","year":"1976","journal-title":"Experientia"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib185","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/np0304114","article-title":"Ponicidin and oridonin are responsible for the antiangiogenic activity of rabdosia r ubescens, a constituent of the herbal supplement PC SPES","volume":"67","author":"Meade-Tollin","year":"2004","journal-title":"J. Nat. Prod."},{"issue":"12","key":"10.1016\/j.prp.2022.153956_bib186","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113830","article-title":"Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling","volume":"9","author":"Dong","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib187","first-page":"1473","article-title":"Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study","volume":"140","author":"Wong","year":"1992","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib188","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/ijc.2910590209","article-title":"Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines","volume":"59","author":"Zabrenetzky","year":"1994","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib189","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00666034","article-title":"The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression","volume":"36","author":"Volpert","year":"1995","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib190","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0002-9440(10)65140-1","article-title":"Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas","volume":"155","author":"Streit","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib191","first-page":"828","article-title":"The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer","volume":"35","author":"Huang","year":"2019","journal-title":"Xi bao yu Fen. zi mian yi xue za zhi Chin. J. Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr620","article-title":"Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status","volume":"5","author":"Wang-Rodriguez","year":"2003","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib193","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4161\/cbt.3.4.737","article-title":"Whence thrombospondin?","volume":"3","author":"Thomas-Tikhonenko","year":"2004","journal-title":"Cancer Biol. Ther."},{"issue":"12","key":"10.1016\/j.prp.2022.153956_bib194","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1096\/fj.99-0931fje","article-title":"The heparin binding 25 kDa fragment of thrombospondin\u20101 promotes angiogenesis and modulates gelatinase and TIMP\u20102 production in endothelial cells","volume":"14","author":"Taraboletti","year":"2000","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib195","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/0008-5472.CAN-03-2446","article-title":"Estrogen receptor \u03b2 inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest","volume":"64","author":"Paruthiyil","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib196","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/ijc.24373","article-title":"Estrogen regulation of thrombospondin\u20101 in human breast cancer cells","volume":"125","author":"Hyder","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib197","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/ijc.33439","article-title":"Thrombospondin\u20104 mediates hyperglycemia\u2010and TGF\u2010beta\u2010induced inflammation in breast cancer","volume":"148","author":"Muppala","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib198","first-page":"821","article-title":"Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients","volume":"2","author":"Yamamoto","year":"1996","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib199","first-page":"1925","article-title":"The correlation between immunohistochernically detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer","volume":"22","author":"Lantzsch","year":"2002","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1006178517505","article-title":"Serum VEGF levels in women with a benign breast tumor or breast cancer","volume":"53","author":"Salven","year":"1999","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib201","first-page":"405","article-title":"Circulating levels of endostatin in cancer patients","volume":"8","author":"Kuroi","year":"2001","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2003.09.018","article-title":"Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer","volume":"204","author":"Zhao","year":"2004","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib203","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.yexcr.2005.03.021","article-title":"Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases","volume":"307","author":"Heljasvaara","year":"2005","journal-title":"Exp. Cell Res."},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib204","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1158\/0008-5472.CAN-05-4012","article-title":"Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo","volume":"66","author":"Nilsson","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/cbt.7.1.5163","article-title":"Biology of breast cancer bone metastasis","volume":"7","author":"Akhtari","year":"2008","journal-title":"Cancer Biol. Ther."},{"issue":"46","key":"10.1016\/j.prp.2022.153956_bib206","doi-asserted-by":"crossref","first-page":"45826","DOI":"10.1074\/jbc.M309024200","article-title":"Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity","volume":"278","author":"Peyruchaud","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"31","key":"10.1016\/j.prp.2022.153956_bib207","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/sj.onc.1205595","article-title":"Decorin suppresses tumor cell-mediated angiogenesis","volume":"21","author":"Grant","year":"2002","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib208","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2353\/ajpath.2008.080275","article-title":"An antimetastatic role for decorin in breast cancer","volume":"173","author":"Goldoni","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib209","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000228253","article-title":"Decorin suppresses bone metastasis in a breast cancer cell line","volume":"77","author":"Araki","year":"2009","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib210","doi-asserted-by":"crossref","first-page":"a003277","DOI":"10.1101\/cshperspect.a003277","article-title":"TGF-\u03b2 biology in mammary development and breast cancer","volume":"3","author":"Moses","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib211","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1172\/JCI846","article-title":"Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor","volume":"101","author":"Moscatello","year":"1998","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib212","doi-asserted-by":"crossref","DOI":"10.1088\/1478-3975\/aac3ba","article-title":"TGF-\u03b2 induces changes in breast cancer cell deformability","volume":"15","author":"Kulkarni","year":"2018","journal-title":"Phys. Biol."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib213","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10549-008-9992-6","article-title":"The effect of thrombospondin-1 on breast cancer metastasis","volume":"114","author":"Yee","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"55","key":"10.1016\/j.prp.2022.153956_bib214","doi-asserted-by":"crossref","first-page":"94091","DOI":"10.18632\/oncotarget.21584","article-title":"ADAMTS1-mediated targeting of TSP-1 by PPAR\u03b4 suppresses migration and invasion of breast cancer cells","volume":"8","author":"Ham","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2022.153956_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117604","article-title":"Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer","volume":"251","author":"Liu","year":"2020","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib216","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4093\/dmj.2014.38.5.330","article-title":"Hyperglycemia as a risk factor for cancer progression","volume":"38","author":"Ryu","year":"2014","journal-title":"Diabetes Metab. J."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib217","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/cancers13061346","article-title":"Hyperglycemia-induced miR-467 drives tumor inflammation and growth in breast cancer","volume":"13","author":"Gajeton","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.prp.2022.153956_bib218","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0002-9440(10)63727-3","article-title":"N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer","volume":"164","author":"Agarwal","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-8-246","article-title":"In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines","volume":"8","author":"Lautenschlaeger","year":"2013","journal-title":"Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib220","first-page":"131","article-title":"Endostar, a modified Endostatin induces vascular normalization to improve chemotherapy efficacy through suppression of Src signaling pathway","volume":"33","author":"Yu","year":"2018","journal-title":"Cancer Biother. Radiopharm."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib221","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0712-8","article-title":"Efficient targeted tumor imaging and secreted endostatin gene delivery by anti-CD105 immunoliposomes","volume":"37","author":"Zhuo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2022.153956_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120429","article-title":"Heparanase-driven sequential released nanoparticles for ferroptosis and tumor microenvironment modulations synergism in breast cancer therapy","volume":"266","author":"Zhang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.prp.2022.153956_bib223","doi-asserted-by":"crossref","DOI":"10.4137\/BCBCR.S23156","article-title":"Altered sirtuin 7 expression is associated with early stage breast cancer","volume":"9","author":"Aljada","year":"2015","journal-title":"Breast Cancer Basic Clin. Res."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib224","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00396-9","article-title":"SIRT7 antagonizes TGF-\u03b2 signaling and inhibits breast cancer metastasis","volume":"8","author":"Tang","year":"2017","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib225","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.7150\/thno.36936","article-title":"TGF-\u03b2 inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity","volume":"10","author":"Panagi","year":"2020","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib226","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/cells8091007","article-title":"Disruption of the NF-\u03baB\/IL-8 signaling axis by sulconazole inhibits human breast cancer stem cell formation","volume":"8","author":"Choi","year":"2019","journal-title":"Cells"},{"issue":"33","key":"10.1016\/j.prp.2022.153956_bib227","doi-asserted-by":"crossref","first-page":"34758","DOI":"10.18632\/oncotarget.5325","article-title":"CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib228","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10585-019-09965-2","article-title":"Discovery of CCL18 antagonist blocking breast cancer metastasis","volume":"36","author":"Liu","year":"2019","journal-title":"Clin. Exp. Metastas."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib229","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ccr.2011.02.006","article-title":"CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3","volume":"19","author":"Chen","year":"2011","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib230","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.3390\/ijms23084408","article-title":"Synergistic anti-angiogenic effect of combined VEGFR kinase inhibitors, lenvatinib, and regorafenib: a therapeutic potential for breast cancer","volume":"23","author":"Bajbouj","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib231","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/biom12020258","article-title":"A new approach to inhibiting triple-negative breast cancer: in vitro, ex vivo and in vivo antiangiogenic effect of BthTx-II, a PLA2-Asp-49 from Bothrops jararacussu Venom","volume":"12","author":"Van Petten de Vasconcelos Azevedo","year":"2022","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr782","article-title":"Recent translational research: antiangiogenic therapy for breast cancer\u2013where do we stand?","volume":"6","author":"Miller","year":"2004","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib233","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.prp.2022.153956_bib234","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/ijc.33108","article-title":"Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER\u2010positive breast cancer","volume":"147","author":"von der Lippe Gythfeldt","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2022.153956_bib235","series-title":"Seminars in Oncology","article-title":"A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer","author":"Cobleigh","year":"2003"},{"issue":"26","key":"10.1016\/j.prp.2022.153956_bib236","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib237","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10549-011-1685-x","article-title":"First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study","volume":"129","author":"Aogi","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"32","key":"10.1016\/j.prp.2022.153956_bib238","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"Brufsky","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.prp.2022.153956_bib239","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.ejca.2011.06.018","article-title":"Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO","volume":"47","author":"Pivot","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib240","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2\u2013negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2022.153956_bib241","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/annonc\/mdq430","article-title":"First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients","volume":"22","author":"Smith","year":"2011","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib242","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","article-title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study","volume":"13","author":"Pierga","year":"2012","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.prp.2022.153956_bib243","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1200\/JCO.2012.44.7912","article-title":"AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer","volume":"31","author":"Gianni","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.prp.2022.153956_bib244","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-17-0874","article-title":"Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis","volume":"23","author":"Ueda","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2022.153956_bib245","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940928","article-title":"Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis","volume":"12","author":"Zou","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.prp.2022.153956_bib246","doi-asserted-by":"crossref","first-page":"ix24","DOI":"10.1093\/annonc\/mdy430.003","article-title":"Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): safety, efficacy and biomarkers","volume":"29","author":"Quintela-Fandino","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2022.153956_bib247","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1158\/1078-0432.CCR-16-0437","article-title":"Tumor-specific uptake of fluorescent bevacizumab\u2013IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study","volume":"23","author":"Lamberts","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.prp.2022.153956_bib248","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1200\/JCO.2018.79.2028","article-title":"Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node\u2013positive and high-risk lymph node\u2013negative breast cancer (E5103)","volume":"36","author":"Miller","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib249","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.7150\/thno.23544","article-title":"DNA methylation signatures predicting bevacizumab efficacy in metastatic breast cancer","volume":"8","author":"Gampenrieder","year":"2018","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.prp.2022.153956_bib250","first-page":"1796","article-title":"Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt\/\u03b2-Catenin signaling pathway","volume":"9","author":"Xie","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib251","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-020-03510-y","article-title":"Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival","volume":"148","author":"Chen","year":"2020","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.prp.2022.153956_bib252","article-title":"A phase II study of rh-endostatin in combination with chemotherapy in human epidermal growth factor receptor 2 (HER-2) negative advanced breast cancer (ABC)","author":"Huang","year":"2020","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.prp.2022.153956_bib253","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/ijc.31217","article-title":"A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first\u2010line therapy for patients with breast cancer (CBCRT 01)","volume":"142","author":"Chen","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib254","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00280-017-3322-9","article-title":"A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors","volume":"79","author":"Haddad","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.prp.2022.153956_bib255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/jpri\/2019\/v30i230265","article-title":"The antiangiogenic effects of tamoxifen might be attributed to receptor binding capacity of its solvent dimethylsulfoxide in breast cancer: a molecular docking study","author":"Ko\u00e7ak","year":"2019","journal-title":"J. Pharm. Res. Int."},{"issue":"4","key":"10.1016\/j.prp.2022.153956_bib256","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/ATVBAHA.116.308791","article-title":"Tamoxifen directly inhibits platelet angiogenic potential and platelet-mediated metastasis","volume":"37","author":"Johnson","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib257","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9742","key":"10.1016\/j.prp.2022.153956_bib258","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib259","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.prp.2022.153956_bib260","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol."},{"issue":"9816","key":"10.1016\/j.prp.2022.153956_bib261","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib262","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib263","article-title":"IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src\/STAT3\/ERK1\/2-mediated EGFR signaling","volume":"1868","author":"Ahmed","year":"2021","journal-title":"Biochim. Biophys. Acta BBA Mol. Cell Res."},{"issue":"2","key":"10.1016\/j.prp.2022.153956_bib264","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/156802662102201211113414","article-title":"Antiangiogenic therapy: challenges and future directions","volume":"21","author":"Su","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.prp.2022.153956_bib265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10456-019-09698-6","article-title":"Vessel co-option and resistance to anti-angiogenic therapy","volume":"23","author":"Kuczynski","year":"2020","journal-title":"Angiogenesis"},{"key":"10.1016\/j.prp.2022.153956_bib266","first-page":"873","article-title":"Current strategies and future directions of antiangiogenic tumor therapy","volume":"35","author":"Zi-Lai","year":"2003","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"6","key":"10.1016\/j.prp.2022.153956_bib267","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129356","article-title":"Expression of HIF-1\u03b1 and markers of angiogenesis are not significantly different in triple negative breast cancer compared to other breast cancer molecular subtypes: implications for future therapy","volume":"10","author":"Yehia","year":"2015","journal-title":"PLoS One"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382200200X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382200200X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:52:06Z","timestamp":1759733526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S034403382200200X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":267,"alternative-id":["S034403382200200X"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.153956","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.153956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153956"}}